Next Phase Newsletter

A newly established venture capital firm based in the USA is investing globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical needs. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2017 and is based in Cambridge, MA. The firm focuses on biotech investments with particular interest in the following indications: oncology, immunology, CNS/neurology, among others. The firm also invests in rare and orphan diseases. The firm is generally stage agnostic, and can invest in anywhere from pre-clinical to pre-launch, commercial stage companies. The firm is capable of investing up to $15M over the life of the company, and is open to acting as either the lead/co-lead or co-investor.

The firm focuses on investments in therapeutics companies across all stages of development, from pre-clinical, clinical, to commercial stage. The firm is most interested in indications of high unmet medical need, including oncology, immunology, neurology, and rare diseases and may seek assets in other indications on a case-by-case basis.

The firm seeks to work with companies backed by an experienced management team with strong scientific expertise. The firm invests in both public and private companies, and is open to acting as either the lead/co-lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A life sciences-focused, impact venture capital firm was founded in 2018 and headquartered in New York with offices in Zurich. The firm aims to achieve meaningful social impact in both developed and emerging markets in addition to financial returns. The firm participates in Series A onward rounds, acting as a lead or co-investor, but can engage with companies earlier depending on the nature of the technology and target indications. Initial check sizes range from USD $3-12M with additional capital generally reserved for follow-ons. The firm is open to global companies.

The firm finances promising life science technologies for high-burden public health challenges and threats. This includes, but is not limited to, infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, and other related global health indications. In terms of technologies, the firm has a broad mandate and invests in vaccines, therapeutics, medical devices, diagnostics, and related enabling technologies. The firm generally likes to see opportunities that have demonstrated safety and generated efficacy signals from clinical trials or similar evaluations and compelling proof-of-concept data.

The firm generally prefers to take a board observer seat at minimum. The firm likes to be an active investor such as being involved in corporate strategy and company building.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A single family office based in the US actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries. 
 
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more. 
 
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2021 and located in Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. The firm invests in European companies. 
 
The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies. 
 
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global pharmaceutical firm specialized in the dermatology sector engages in partnerships with early stage companies; these relationships may take a variety of forms, but in most cases the firm forms a partnership around an asset and does not act as a minority equity investor. The firm partners with dermatology startups all around the globe. 
 
The firm is interested in therapeutic programs in the dermatology space, including in acne, dermatology-oncology, and rare diseases of the skin.  The firm will consider partnerships at any stage of development but will only make early stage partnerships if the asset’s risk profile is reasonable. 
 
There are no specific requirements for company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.